According to Persistence Market Research, the pharmaceutical glass packaging market was valued at US$23 billion in 2025 and is projected to reach US$44.3 billion by 2032, expanding at a CAGR of 9.8% during the forecast period. Growth is being driven less by volume than by specification. Manufacturers increasingly need glass that can withstand high-speed filling lines, resist chemical interaction with sensitive biologics, and meet strict regulatory requirements for sterile injectable drugs.
Delamination Risk is Pushing Manufacturers Toward Pure Glass Chemistry
Traditional borosilicate glass has been used by the pharmaceutical industry for more than a century, but it has a well-known limitation. Under certain storage and formulation conditions, its inner surface can release microscopic glass flakes into the drug, a phenomenon known as delamination. For biologics with high pH levels or long shelf lives, this risk can lead to product recalls and delays in regulatory approvals.
To address this challenge, manufacturers are redesigning the glass itself rather than only improving production processes. Pfizer and Corning recently signed a multi-year supply agreement for Corning's Valor Glass, an aluminosilicate glass developed to reduce the delamination risk associated with conventional borosilicate vials while also improving resistance to breakage during high-speed filling. This partnership reflects a broad industry shift, where advanced glass chemistry is becoming as important as manufacturing quality in pharmaceutical packaging.
Self-Injectable Medicines Are Driving Packaging Innovation
As treatments for autoimmune diseases, cancer, and metabolic disorders now move from hospitals to patients' homes, prefilled syringes are gradually replacing traditional vials. According to Persistence Market Research, the global prefilled syringes market is predicted to be valued at US$10 billion in 2026 and reach US$19.3 billion by 2033, expanding at a CAGR of 9.8% in the forecast period. Glass continues to be the preferred material for syringe barrels because it provides the stability needed for sensitive biologic formulations.
This trend is already exhibited in new drug approvals. For example, in April 2025, argenx received Food and Drug Administration (FDA) approval for a prefilled syringe version of its VYVGART Hytrulo therapy, enabling patients to self-administer the treatment at home in about 20 to 30 seconds. Such approvals highlight the growing need for container-closure systems that maintain drug stability throughout shelf life, thereby increasing demand for high-quality glass packaging for complex biologic formulations.
Digital Inspection Technology is Becoming the New Quality Standard
Producing chemically stable glass is only part of the challenge. Manufacturers must also ensure that every vial leaving the production line is free from cracks, particulates, and cosmetic defects. As fill-finish operations become faster, manual inspection is finding it very difficult to detect the subtle defects associated with high-viscosity and lyophilised drug formulations.
To address this challenge, manufacturers are adopting inspection systems that combine advanced equipment with AI-driven defect detection. For example, Stevanato Group has integrated AI-supported defect classification into its inspection platforms for highly concentrated and sensitive biologics.
Another example is SGD Pharma, which introduced its Sealian coating platform at Pharmapack Europe in January 2025. The internal surface treatment creates a protective barrier inside glass vials, helping preserve drug integrity throughout the product's shelf life while making visual inspection easier. Together, these innovations show that inspection technology and surface engineering are becoming key areas of innovation rather than simply final quality checks.
Companies Are Building a Strong and Green Glass Supply Chain
Competition is changing not only how pharmaceutical glass is produced but also who supplies it. Companies are expanding their capabilities through acquisitions to strengthen their position in high-value injectable packaging. For example, Gerresheimer acquired Bormioli Pharma in 2024 to expand its moulded glass portfolio and announced in 2025 that it would focus more on high-margin injectable packaging instead of commodity glass.
A similar strategy is being followed across the industry. For example, SGD Pharma acquired Alphial in Italy in the fourth quarter of 2025, adding ampoule, vial, and ready-to-use production capacity across Europe. At the same time, sustainability is becoming a key competitive advantage. Driven by the European Medicines Agency's regulatory environment and the EU's broad sustainability goals, manufacturers are investing in electric furnaces, high recycled-cullet content, and lightweight glass formats.
Suppliers Combining Chemistry, Digital Quality, and Scale Will Likely Define the Next Decade
The next phase of growth in pharmaceutical glass packaging will likely be defined less by how much glass companies can produce and more by how precisely they can engineer it. Winning suppliers will need chemistry that survives sensitive biologic formulations, inspection systems that catch defects invisible to the human eye, and manufacturing footprints that satisfy regulators and sustainability mandates at the same time. For an industry that has long treated glass as a commodity, that combination represents a genuine reset, one in which the material inside every vial and syringe is becoming almost as engineered as the drug it protects.
